Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes

Joe M. Horvatinovich, Elizabeth W. Grogan, Marcus Norris, Alexander Steinkasserer, Henrique Lemos, Andrew L. Mellor, Irina Y. Tcherepanova, Charles A. Nicolette, Mark A. DeBenedette

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The transmembrane protein CD83, expressed on APCs, B cells, and T cells, can be expressed as a soluble form generated by alternative splice variants and/or by shedding. Soluble CD83 (sCD83) was shown to be involved in negatively regulating the immune response. sCD83 inhibits T cell proliferation in vitro, supports allograft survival in vivo, prevents corneal transplant rejection, and attenuates the progression and severity of autoimmune diseases and experimental colitis. Although sCD83 binds to human PBMCs, the specific molecules that bind sCD83 have not been identified. In this article, we identify myeloid differentiation factor-2 (MD-2), the coreceptor within the TLR4/MD-2 receptor complex, as the high-affinity sCD83 binding partner. TLR4/MD-2 mediates proinflammatory signal delivery following recognition of bacterial LPSs. However, altering TLR4 signaling can attenuate the proinflammatory cascade, leading to LPS tolerance. Our data show that binding of sCD83 to MD-2 alters this signaling cascade by rapidly degrading IL-1R-associated kinase-1, leading to induction of the anti-inflammatory mediators IDO, IL-10, and PGE2 in a COX-2-dependent manner. sCD83 inhibited T cell proliferation, blocked IL-2 secretion, and rendered T cells unresponsive to further downstream differentiation signals mediated by IL-2. Therefore, we propose the tolerogenic mechanism of action of sCD83 to be dependent on initial interaction with APCs, altering early cytokine signal pathways and leading to T cell unresponsiveness.

Original languageEnglish (US)
Pages (from-to)2286-2301
Number of pages16
JournalJournal of Immunology
Volume198
Issue number6
DOIs
StatePublished - Mar 15 2017

Fingerprint

Monocytes
T-Lymphocytes
Interleukin-2
Cell Proliferation
Graft Rejection
Colitis
Dinoprostone
Interleukin-10
Autoimmune Diseases
Allografts
Signal Transduction
B-Lymphocytes
Anti-Inflammatory Agents
Phosphotransferases
Cytokines
Proteins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Horvatinovich, J. M., Grogan, E. W., Norris, M., Steinkasserer, A., Lemos, H., Mellor, A. L., ... DeBenedette, M. A. (2017). Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes. Journal of Immunology, 198(6), 2286-2301. https://doi.org/10.4049/jimmunol.1600802

Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes. / Horvatinovich, Joe M.; Grogan, Elizabeth W.; Norris, Marcus; Steinkasserer, Alexander; Lemos, Henrique; Mellor, Andrew L.; Tcherepanova, Irina Y.; Nicolette, Charles A.; DeBenedette, Mark A.

In: Journal of Immunology, Vol. 198, No. 6, 15.03.2017, p. 2286-2301.

Research output: Contribution to journalArticle

Horvatinovich, JM, Grogan, EW, Norris, M, Steinkasserer, A, Lemos, H, Mellor, AL, Tcherepanova, IY, Nicolette, CA & DeBenedette, MA 2017, 'Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes', Journal of Immunology, vol. 198, no. 6, pp. 2286-2301. https://doi.org/10.4049/jimmunol.1600802
Horvatinovich JM, Grogan EW, Norris M, Steinkasserer A, Lemos H, Mellor AL et al. Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes. Journal of Immunology. 2017 Mar 15;198(6):2286-2301. https://doi.org/10.4049/jimmunol.1600802
Horvatinovich, Joe M. ; Grogan, Elizabeth W. ; Norris, Marcus ; Steinkasserer, Alexander ; Lemos, Henrique ; Mellor, Andrew L. ; Tcherepanova, Irina Y. ; Nicolette, Charles A. ; DeBenedette, Mark A. / Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes. In: Journal of Immunology. 2017 ; Vol. 198, No. 6. pp. 2286-2301.
@article{ab9a0319f0644a36b61591403b27259e,
title = "Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes",
abstract = "The transmembrane protein CD83, expressed on APCs, B cells, and T cells, can be expressed as a soluble form generated by alternative splice variants and/or by shedding. Soluble CD83 (sCD83) was shown to be involved in negatively regulating the immune response. sCD83 inhibits T cell proliferation in vitro, supports allograft survival in vivo, prevents corneal transplant rejection, and attenuates the progression and severity of autoimmune diseases and experimental colitis. Although sCD83 binds to human PBMCs, the specific molecules that bind sCD83 have not been identified. In this article, we identify myeloid differentiation factor-2 (MD-2), the coreceptor within the TLR4/MD-2 receptor complex, as the high-affinity sCD83 binding partner. TLR4/MD-2 mediates proinflammatory signal delivery following recognition of bacterial LPSs. However, altering TLR4 signaling can attenuate the proinflammatory cascade, leading to LPS tolerance. Our data show that binding of sCD83 to MD-2 alters this signaling cascade by rapidly degrading IL-1R-associated kinase-1, leading to induction of the anti-inflammatory mediators IDO, IL-10, and PGE2 in a COX-2-dependent manner. sCD83 inhibited T cell proliferation, blocked IL-2 secretion, and rendered T cells unresponsive to further downstream differentiation signals mediated by IL-2. Therefore, we propose the tolerogenic mechanism of action of sCD83 to be dependent on initial interaction with APCs, altering early cytokine signal pathways and leading to T cell unresponsiveness.",
author = "Horvatinovich, {Joe M.} and Grogan, {Elizabeth W.} and Marcus Norris and Alexander Steinkasserer and Henrique Lemos and Mellor, {Andrew L.} and Tcherepanova, {Irina Y.} and Nicolette, {Charles A.} and DeBenedette, {Mark A.}",
year = "2017",
month = "3",
day = "15",
doi = "10.4049/jimmunol.1600802",
language = "English (US)",
volume = "198",
pages = "2286--2301",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - Soluble CD83 inhibits T cell activation by binding to the TLR4/MD-2 complex on CD14+ monocytes

AU - Horvatinovich, Joe M.

AU - Grogan, Elizabeth W.

AU - Norris, Marcus

AU - Steinkasserer, Alexander

AU - Lemos, Henrique

AU - Mellor, Andrew L.

AU - Tcherepanova, Irina Y.

AU - Nicolette, Charles A.

AU - DeBenedette, Mark A.

PY - 2017/3/15

Y1 - 2017/3/15

N2 - The transmembrane protein CD83, expressed on APCs, B cells, and T cells, can be expressed as a soluble form generated by alternative splice variants and/or by shedding. Soluble CD83 (sCD83) was shown to be involved in negatively regulating the immune response. sCD83 inhibits T cell proliferation in vitro, supports allograft survival in vivo, prevents corneal transplant rejection, and attenuates the progression and severity of autoimmune diseases and experimental colitis. Although sCD83 binds to human PBMCs, the specific molecules that bind sCD83 have not been identified. In this article, we identify myeloid differentiation factor-2 (MD-2), the coreceptor within the TLR4/MD-2 receptor complex, as the high-affinity sCD83 binding partner. TLR4/MD-2 mediates proinflammatory signal delivery following recognition of bacterial LPSs. However, altering TLR4 signaling can attenuate the proinflammatory cascade, leading to LPS tolerance. Our data show that binding of sCD83 to MD-2 alters this signaling cascade by rapidly degrading IL-1R-associated kinase-1, leading to induction of the anti-inflammatory mediators IDO, IL-10, and PGE2 in a COX-2-dependent manner. sCD83 inhibited T cell proliferation, blocked IL-2 secretion, and rendered T cells unresponsive to further downstream differentiation signals mediated by IL-2. Therefore, we propose the tolerogenic mechanism of action of sCD83 to be dependent on initial interaction with APCs, altering early cytokine signal pathways and leading to T cell unresponsiveness.

AB - The transmembrane protein CD83, expressed on APCs, B cells, and T cells, can be expressed as a soluble form generated by alternative splice variants and/or by shedding. Soluble CD83 (sCD83) was shown to be involved in negatively regulating the immune response. sCD83 inhibits T cell proliferation in vitro, supports allograft survival in vivo, prevents corneal transplant rejection, and attenuates the progression and severity of autoimmune diseases and experimental colitis. Although sCD83 binds to human PBMCs, the specific molecules that bind sCD83 have not been identified. In this article, we identify myeloid differentiation factor-2 (MD-2), the coreceptor within the TLR4/MD-2 receptor complex, as the high-affinity sCD83 binding partner. TLR4/MD-2 mediates proinflammatory signal delivery following recognition of bacterial LPSs. However, altering TLR4 signaling can attenuate the proinflammatory cascade, leading to LPS tolerance. Our data show that binding of sCD83 to MD-2 alters this signaling cascade by rapidly degrading IL-1R-associated kinase-1, leading to induction of the anti-inflammatory mediators IDO, IL-10, and PGE2 in a COX-2-dependent manner. sCD83 inhibited T cell proliferation, blocked IL-2 secretion, and rendered T cells unresponsive to further downstream differentiation signals mediated by IL-2. Therefore, we propose the tolerogenic mechanism of action of sCD83 to be dependent on initial interaction with APCs, altering early cytokine signal pathways and leading to T cell unresponsiveness.

UR - http://www.scopus.com/inward/record.url?scp=85014710371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014710371&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1600802

DO - 10.4049/jimmunol.1600802

M3 - Article

VL - 198

SP - 2286

EP - 2301

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -